Novo Nordisk (NVO) Stock

Novo Nordisk Stock Details, Movements and Public Alerts

Stock Details

Novo Nordisk (NVO), a prominent company in the life sciences sector within the pharmaceutical preparations industry, is based in USA and primarily trades on the NYSE.Currently, the stock is trading at $53.93. Over the past 52 weeks, it has ranged between $53.51 and $137.52. This places the current price at 39.2% of its 52-week high and 0.8% above its 52-week low. Recent trading volume was recorded at 110,543,952. The 14-day Relative Strength Index (RSI) stands at 56.73, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $66.31 by 18.67%. Similarly, it is below its 200-day moving average of $93.79 by 42.50%. The MACD histogram is 0.60, indicating bullish momentum (MACD Line: 1.25, Signal Line: 0.64). The International Securities Identification Number (ISIN) for this stock is US6701002056.

Market Cap

$304.60B

52-Week High

$137.52

-60.78% from high

52-Week Low

$53.51

+0.78% from low

Avg Daily Volume

110,543,952

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

18.62

Near market average

Forward P/E

16.58

Earnings expected to grow

PEG Ratio

1.31

Reasonably valued

Price to Book

14.03

EV/EBITDA

13.79

EPS (TTM)

$3.68

Price to Sales

1.00

Beta

0.22

Less volatile than market

How is NVO valued relative to its earnings and growth?

Novo Nordisk trades at a P/E ratio of 18.62, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 16.58 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 1.31 indicates reasonable value when growth is considered.

What is NVO's risk profile compared to the market?

With a beta of 0.22, Novo Nordisk is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 14.03 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

34.50%

Operating Margin

49.70%

Return on Equity

88.10%

Return on Assets

23.30%

Revenue Growth (YoY)

19.50%

Earnings Growth (YoY)

15.00%

How profitable and efficient is NVO's business model?

Novo Nordisk achieves a profit margin of 34.50%, meaning it retains $34.50 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 49.70% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 88.10% and ROA at 23.30%, the company generates strong returns on invested capital.

What are NVO's recent growth trends?

Novo Nordisk's revenue grew by 19.50% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 15.00% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against PHARMACEUTICAL PREPARATIONS industry averages for proper context.

Dividend Information

Dividend Per Share

$11.40

Dividend Yield

2.36%

Ex-Dividend Date

3/31/2025

Dividend Date

4/8/2025

What dividend income can investors expect from NVO?

Novo Nordisk offers a dividend yield of 2.36%, paying $11.40 per share annually. This above-average yield of 2-4% provides meaningful income while still allowing the company to reinvest for growth. It compares favorably to the S&P 500 average and offers competitive returns versus bonds in the current rate environment. To receive the next dividend, shares must be purchased before the ex-dividend date of 3/31/2025.

How reliable is NVO's dividend for long-term investors?

The dividend sustainability can be assessed through the payout ratio - Novo Nordisk pays $11.40 per share in dividends against earnings of $3.68 per share, resulting in a payout ratio of 100.00%. This very high payout exceeding 90% raises sustainability concerns, as nearly all earnings go to dividends. Any earnings decline could force a dividend cut. The next dividend payment is scheduled for 4/8/2025.

Company Size & Market

Shares Outstanding

3.37B

Book Value/Share

$31.21

Asset Type

Common Stock

What is NVO's market capitalization and position?

Novo Nordisk has a market capitalization of $304.60B, classifying it as a mega-cap stock (over $200B). These are the largest, most established companies globally, typically offering stability and liquidity but with more modest growth potential. Mega-caps often pay dividends and weather economic downturns better than smaller companies. With 3.37B shares outstanding, the company's ownership is widely distributed. As a major player in the PHARMACEUTICAL PREPARATIONS industry, it competes with other firms in this sector.

How does NVO's price compare to its book value?

Novo Nordisk's book value per share is $31.21, while the current stock price is $53.93, resulting in a price-to-book (P/B) ratio of 1.73. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$92.83

72.13% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

How reliable are analyst predictions for NVO?

12 analysts cover NVO with 50% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $92.83 implies 72.1% upside, but targets are often adjusted to follow price moves rather than predict them.

What is the Wall Street consensus on NVO?

Current analyst recommendations:2 Strong Buy, 4 Buy, 4 Hold, 1 Sell, 1 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 1, 2025, 03:01 AM

Technical Indicators

RSI (14-day)

56.73

Neutral

50-Day Moving Average

$66.31

-18.67% below MA-50

200-Day Moving Average

$93.79

-42.50% below MA-200

MACD Line

1.25

MACD Signal

0.64

MACD Histogram

0.60

Bullish

What does NVO's RSI value tell investors?

The RSI (Relative Strength Index) for NVO is currently 56.73, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this shows mixed signals requiring careful analysis.

How should traders interpret NVO's MACD and moving average crossovers?

MACD analysis shows the MACD line at 1.25 above the signal line at 0.64, with histogram at 0.60. This bullish crossover suggests upward momentum is building. The 50-day MA ($66.31) is below the 200-day MA ($93.79), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Jun 4, 2025, 07:27 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for NVO and get notified when the price changes.

Stay Ahead of the Market with Novo Nordisk Alerts

Set up price alerts for Novo Nordisk and get notified instantly when the price hits your target. Never miss an important price movement again.